Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bliv vs Get Thin MD

Bliv
Graded #187

Lower grade

vs+0.4000000000000057
Get Thin MD
Graded #179

Higher grade

The verdict

Get Thin MD takes it — 66.7/100 to 66.3/100, but only just.

Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu… Bliv is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBliv +21
71
50
Dose & formulationGet Thin MD +13
64
77
Clinical oversightGet Thin MD +8
82
90
Labs & monitoringGet Thin MD +2
53
55
FulfillmentGet Thin MD +26
65
91
Contract termsBliv +25
45
20
Bliv · left barGet Thin MD · right bar

The numbers

MetricBlivGet Thin MD
WeighScore66.3/10066.7/100
GradeCC
Scorecard rank#187#179
Semaglutide$116/mo (as low as, varies by plan and eligibility, compounded)$199/mo (compounded)
Tirzepatide$199/mo (as low as, varies by plan and eligibility, compounded)$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Bliv

Graded #187 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
  • A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
  • The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
  • The only figure smaller than the advertised rate is a $29 CareCredit/Klarna instalment, which is a financing payment rather than the price of a month of medication
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Get Thin MD

Graded #179 · C

Strengths

  • 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
  • Price-lock promise — same price every dose, no hidden fees
  • Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
  • Nationwide availability with async evaluation — no in-person visit
  • Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols

Where it loses points

  • Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
  • Pharmacy partners not named — no way to verify the compounding source or batch testing
  • Claims nationwide coverage but publishes no state list — confirm at intake
  • Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
  • Wide wellness funnel may steer you toward non-weight-loss protocols

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard